Matrix metalloproteinase (MMP)-2 and MMP-9 expression in tumor infiltrating CD3 lymphocytes from women with endometrial cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 8, 2012, Pages 1303-1309

  Jedryka, Marcin ^a   Chrobak, Agnieszka ^b   Anna, Chelmonska Soyta ^b   Gawron, Daria ^c   Halbersztadt, Alicja ^b   Wojnar, Andrzej ^d   Kornafel, Jan ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

^d Wroclaw   (Poland)

Author keywords

CD3 lymphocytes; Endometrial cancer; MMP 2; MMP 9

Indexed keywords

CD3 ANTIGEN; GELATINASE A; GELATINASE B; MESSENGER RNA;

ARTICLE; CD3+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD3; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES, TUMOR-INFILTRATING; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84867280957     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318269e27b     Document Type: Article

References (35)

1. Ambros RA, Kurman RJ, Diana KL, et al. Combined assessment of vascular invasion and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of uterine corpus. Cancer. 1992;69:1424-1431.
2. Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol. 1992;45:235-239.
3. Zaino RJ, Kurman RJ, Diana KL, et al. Pathologic models to predict outcome for women with endometrial adenocarcinoma. Cancer. 1996;77:1115-1121.
4. Ghering PA, Van Le L, Olatidoye B, et al. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 1999;8986:2083-2089.
5. Bell JG, Minninck A, Reid GC, et al. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecol Oncol. 1997;66:388-392.
6. Wallace AE, Gibson DA, Saunders PTK, et al. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010;206:141-157.
7. Di Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002;94:1466-1475.
8. Woesner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
9. Nomura H, Fujimoto N, Seiki M, et al. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinoma. Int J Cancer 1996;69:9-16.
10. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch. 2001;438:121-128.
11. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors and the activatorMT1-MMP in primary breast carcinomas. J Pathol. 1999;189:161-168.
12. Sakata K, Shigemasa K, Nagai N, et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17:673-681.
13. Iurlaro M, Loverro G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinases 2 and 9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest. 1999;29:793-801.
14. Graesslin O, Cortez A, Uzan C et al. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer. 2006;16:1911-1917.
15. Soini Y, Alarakolla E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol. 1997;28:220-226.
16. Kondratiev S, Sabo E, Yakirevich E, et al. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10:4450-4456.
17. Silverberg SG, Sasano N, Yajima A. Endometrial carcinoma in Miyagi prefecture, Japan: histopathological analysis of cancer registry Y based series and comparison with cases in American women. Cancer. 1982;449:1504-1510.
18. Giatromolaki A, Bates GJ, Koukourakis MI, et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intramural angiogenesis in endometrial cancer. Gynecol Oncol. 2008;110:216-221.
19. Remmele W, Hildebrand U, Hienz H, et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986;409:127-147.
20. Lan YQ, Zhang C, Xiao JH, et al. Suppression of IJB> increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. Molecular Vision. 2009;15:1977-1987.
21. Ye H, Yu T, Temam S, et al. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics. 2008;9:69.
22. Schropfer A, Kammerer U, Kapp M et al. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer 2010;10:553.
23. Planaguma J, Liljestrom M. Matrix metalloproteinase2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol. 2011;42:57-67.
24. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol. 1993;9:541-573.
25. Iyer V, Pumiglia K, DiPersio CM. Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci. 2005;15:1185-1195.
26. Yuta S, Wakana S, Rikio S, et al. Potentation of cell invasion and matrix metalloproteinase production by alpha3beta1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clin Exp Met. 2010;4:197-205.
27. Vivinus-Nebot M, Rousselle P, Breittmayer JP, et al. Mature human thymocytes migrate on laminin-5 with activation of metalloproteinase-14 and cleavage of CD44. J Immunol. 2004;172:1397-1406.
28. Shenoy PS, Uniyal S, Miura K et al. Beta1 integrin-extracellular matrix protein interaction modulates the migratory response to chemokine stimulation. Biochem Cell Biol. 2001; 79:399-407.
29. Yamazawa K, Seki K, Matsui K, et al. Significance of perivascular lymphocytic infiltrates in endometrial carcinoma. Cancer. 2001;91:1777-1784.
30. Chang WC, Huang SC, Torng PL et al. Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma. Cancer. 2005;15:1073-1080.
31. Miyatake T, Tringler B, Liu W et al. -H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol. 2007; 106:119-127.
32. Lacraz S, Nicod L, Galve-de Rochemonteix B et al. Suppression of metalloproteinases biosynthesis in human alveolar macrophages by interleukin-4. Clin Invest. 1992;90:382-388.
33. Abraham M, Shapiro S, Lahat N, Miller A. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol. 2002;14:1449-1457.
34. Abraham M, Shapiro S, Karni A et al. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol. 2005;163: 157-164.
35. Bor-Ching S, Su-Ming H, Hong-Nerng H, et al. A novel role of metalloproteinases in cancer-mediated immunosuppression. Cancer Res. 2001;61:237-242.